Nkarta Inc (NKTX) Directors and Executive Officers

Officers & Directors

Executives:

1. Paul J. Hastings - Chief Executive Officer and Director
2. Alyssa Levin - Chief Financial and Business Officer

Board of Directors:

1. Simeon George - Director
2. Ali Behbahani - Director
3. Leone Patterson - Director
4. Zachary Scheiner - Director
5. Fouad Azzam - Director
6. Angela Thedinga - Director
7. Michael Dybbs - Director ,

Nkarta Inc currently has 108 employees.

News about Nkarta Inc Key Personnel

Nkarta Bolsters Leadership Team to Advance Pioneering NK Cell Therapies

Nkarta Strengthens Leadership Team with New President and Chief Medical Officer
July 16, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a pioneering biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced significant changes to its leadership team. The company welcomes the appointment of Dr. Nadir Mahmood as President, who will share executive leadership responsibilities with Chief Executive Officer Paul J. Hastings. Additionally, Nkarta has expanded the role of Dr. David R. Shook, appointing him as Chief Medical Officer and Head of Research and Development. These changes reflect Nkarta s commitment to advancing its innovative cell therapy pipeline and driving growth i...

Nkarta's Underwritten Offering Amidst Financial Struggles Sparks Debate Over Future Growth Potential in Biopharmaceutical Sector

Nkarta s Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical Sector
SOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in the development of engineered natural killer (NK) cell therapies, recently announced the pricing of an underwritten offering, aiming to raise $240 million. However, this news comes amid concerns regarding the company s financial performance, particularly with a cumulative net loss of $122 million recorded during the 12 months ending in the third quarter of 2023. This indicates a negative return on investment (ROI) of -29.38%, highlighting potential challenges for investors.